Rennova Health, Inc. · OTC:RNVA
Rennova Health — CollabRx — Merger or Acquisition (September 2015)
27 slides from Rennova Health's merger presentation, Sep 23, 2015
Slide 1: Expert Systems for Precision Medicine Investor Presentation - Pre-merger
Expert Systems for Precision Medicine Investor Presentation - Pre-merger (with Supplement) 1
Slide 2: Safe Harbor
Safe Harbor This presentation includes forward-looking statements about CollabRx's and Medytox Solution’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations a
Slide 3: Participants in Solicitation and Additional Information
Participants in Solicitation and Additional Information CollabRx (NASDAQ: CLRX), Medytox (OTCQB: MMMS), and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from CollabRx and Medytox stockholders with respect to the p
Slide 4: Strategy and Rationale for Merger
Strategy and Rationale for Merger Medytox’s strategy is to provide IT systems to target customers as a way to automate key manual processes, manage the complete revenue cycle, and drive orders and loyalty for lab services.A central system for order entry and tracking (Advantage) is provided free of
Slide 5: Overview of CollabRx
Overview of CollabRx A leading provider of expert-informed clinical decision support systems for diagnostic labs, physicians and patients navigating advanced cancer. We address the emerging market for genomic testing in cancer with an industry-leading, scalable solution for evidence-based therapy se
Slide 6: Overview of Medytox: vertically-integrated clinical laboratory testing and business solutions
A vertically-integrated provider of clinical laboratory testing and business solutions to drug rehab and pain management clinics and to private physician practices nationwide. Name Location Services Biohealth Laboratories Miami, FL Screening and clinical International Technologies Waldwick, NJ Scree
Slide 7: Rationale for the Merger - Strategic
Rationale for the Merger - Strategic Strategic: adding to existing test menu, while building an end-to-end solution in cancer testing. Medytox plans to enter testing markets in clinical diagnostics, including cancer and diabetes.Opportunity exists to acquire a genomic testing lab or to develop one i
Slide 8: Rationale for the Merger - Operational
Rationale for the Merger - Operational Operational: offering centralized management and expertise for controlled growth and profit. Medytox maintains a corporate structure that includes key areas of expertise for health care companies, such as:Marketing and SalesComplianceLegalHIPAA-compliant ITDuri
Slide 9: Rationale for the Merger - Financial
Rationale for the Merger - Financial Financial: building a highly liquid platform on NASDAQ for a broader investor base and access to capital. Medytox has a strong base of revenue and profit in core business of toxicology testing.Medytox has a track record of on-boarding capabilities and expertise a
Slide 10: Combination enables entry into pharmacogenomics management
Combination enables entry into pharmacogenomics management Oncology Care Management Technologies and Services Test selection and ordering Lab test execution Bioinformatics Analysis Clinical interpretation and Reporting Therapy selection Coverage review and Pre-authorization Therapy Administration Mo
Slide 11: Medytox History and Outlook
Medytox History and Outlook Organic Growth and Diversification 2011 2012 2013 2014 2015 11
Slide 12: Medytox products and services
Pain Management Behavioral Health Self Directed Testing* POC Medical Devices* Behavioral Health EHR Ambulatory EHR DME* Interpretation: Making diagnostics data meaningful Cancer Neurotransmitters* Esoteric Testing* Self Directed Tests* Medytox Advantage is a proprietary ordering and reporting softwa
Slide 13: Drug and Alcohol Rehab Market for Medytox
Drug and Alcohol Rehab Market for Medytox Total Market Size – estimated at $35 Billion* Large and growing number of facilities in a fragmented market:Between 14,500 to 16,700 outpatient clinics*. Top 50 control less than 20% of the market*. Market growth from high demand:Over 23 million Americans ar
Slide 14: Chronic Pain Management Market for Medytox
Chronic Pain Management Market for Medytox Total Market Size – estimated at $2-$4 billion*Large and growing number of clinics in a fragmented market*:Private clinics in the U.S. estimated between 1,500 to 2,500. More than 6,800 doctors specialize in pain management and more than 600,000 doctors are
Slide 15: End Market Drivers Favor Growth for Combined Company
End Market Drivers Favor Growth for Combined Company Lab Services:Drivers are primarily secular growth and attention to physician - patient compliance.Largest growth markets for rehab centers are warm weather, coastal states of Florida and California.Physicians are under increasing scrutiny to ensur
Slide 16: Medytox Solutions Historic Financial Performance
Medytox Solutions Historic Financial Performance (Dollars in Thousands) Annual Performance since Formation 16
Slide 17: Specialist Toxicology Testing Landscape
Specialist Toxicology Testing Landscape Competitor Ownership Market Share (%) Revenues 2014 (millions) 2014/2013 Revenue Growth Alere Toxicology Private 14% $331 (4-5%) Quest Diagnostics NYSE:DGX 9% $219 +4% Medytox Solutions OTCQB: MMMS 2% $58 +38% ALL OTHERS <75% $1,842 +7% AIT Laboratories Privat
Slide 18: Near to mid-term Growth Strategy for Combined Company
Near to mid-term Growth Strategy for Combined Company Continue to grow core lab business by offering high quality testing, a comprehensive menu, and superior customer service, supported by:Medytox Advantage™ – a proprietary web-based lab ordering and reporting software offering,a national presence w
Slide 19: Estimated Timeline for Merger and Rebranding
Estimated Timeline for Merger and Rebranding July Oct August Sept At closing, the surviving listed entity will will be rebranded as: Rennova Health, Inc., NASDAQ: RNVA. NASDAQ Initial Listing Application and Qualification 19
Slide 20: NASDAQ Initial Listing Criteria
NASDAQ Initial Listing Criteria Requirement Current Standard* Medytox CollabRx Stockholder’s equity $5 million ✔ Market value of publicly held shares $15 million ✔ Operating history 2 years ✔ Market value of listed securities $50 million ✔ Net Income from continuing operations $750 thousand ✔ Public
Slide 21: Post-merger Management Team
Post-merger Management Team Seamus Lagan, Chief Executive Officer. Directed the formation of Medytox and its transition from its former business via Alcimede, LLC, a consulting firm he founded in 2007 that specializes in restructuring, development and management of small companies in both the privat
Slide 22: Post-merger Management Team (continued)
Post-merger Management Team (continued) Steven Burdelski, Chief Compliance Officer. Mr. Burdelski previously served as an executive manager of the Federal Bureau of Investigation (FBI), where he was responsible for strategic planning and leadership of all FBI investigative programs such as criminal,
Slide 23: Post-merger Board of Directors
Post-merger Board of Directors INSIDE DIRECTORS (2):Thomas R. Mika, Executive Chairman of Medytox (effective with the merger) and CEO, CollabRx, Inc. Mr. Mika served from 2005 – 2012 as Chairman & CEO of Tegal Corporation and was its EVP/CFO since 2002. He has extensive prior experience in executive
Slide 24: Post-merger Board of Directors
Post-merger Board of Directors Benjamin Frank, director of Medytox since 2013. Retired lawyer and businessman, with particular experience in healthcare, foreign trade, retail, business development and government. After practicing as an attorney, from 1962 to 1966, he was a Senior Vice President and
Slide 25: Summary Rationale for Merger
Summary Rationale for Merger Medytox model for organic growth combined with diversification drives current and future company value.Track record of profitable growth and adherence with laws and regulations.Initial revenue diversification realized through sales by wholly-owned subsidiaries.Developmen
Slide 26: Contacts
Contacts Please contact the following individuals for additional information:Seamus Lagan, CEO – Medytox Solutions, Inc. slagan@medytoxsolutionsinc.comThomas Mika, CEO – CollabRx, Inc. tmika@collabrx.comInvestor and Public Relations:Sebastien Sainsbury, Medytox Solutions, Inc.ssainsbury@medytoxsolut
Slide 27: www.medytoxsolutionsinc.com www.collabrx.com
www.medytoxsolutionsinc.comwww.collabrx.com 27